MXPA03010523A - Antibodies specific for cd44v6. - Google Patents

Antibodies specific for cd44v6.

Info

Publication number
MXPA03010523A
MXPA03010523A MXPA03010523A MXPA03010523A MXPA03010523A MX PA03010523 A MXPA03010523 A MX PA03010523A MX PA03010523 A MXPA03010523 A MX PA03010523A MX PA03010523 A MXPA03010523 A MX PA03010523A MX PA03010523 A MXPA03010523 A MX PA03010523A
Authority
MX
Mexico
Prior art keywords
antibody
antibody proteins
cd44v6
antibodies specific
antibodies
Prior art date
Application number
MXPA03010523A
Other languages
Spanish (es)
Inventor
J Miglietta John
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MXPA03010523A publication Critical patent/MXPA03010523A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Abstract

The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
MXPA03010523A 2001-05-18 2002-05-17 Antibodies specific for cd44v6. MXPA03010523A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
US23514701P 2001-09-26 2001-09-26
PCT/EP2002/005467 WO2002094879A1 (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6

Publications (1)

Publication Number Publication Date
MXPA03010523A true MXPA03010523A (en) 2004-07-01

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010523A MXPA03010523A (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6.

Country Status (18)

Country Link
EP (1) EP1397387A1 (en)
JP (1) JP2005504517A (en)
CN (1) CN1541226A (en)
AR (1) AR036154A1 (en)
BR (1) BR0210905A (en)
CA (1) CA2443437A1 (en)
CZ (1) CZ20033476A3 (en)
EA (1) EA200301169A1 (en)
EC (1) ECSP034838A (en)
EE (1) EE200300569A (en)
HU (1) HUP0400030A3 (en)
MX (1) MXPA03010523A (en)
PE (1) PE20021098A1 (en)
PL (1) PL365735A1 (en)
SK (1) SK15592003A3 (en)
WO (1) WO2002094879A1 (en)
YU (1) YU91403A (en)
ZA (1) ZA200307365B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP3101034A1 (en) 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
JP4949373B2 (en) 2005-03-10 2012-06-06 モルフォテック、インク． Anti-mesothelin antibody
WO2006116592A2 (en) 2005-04-22 2006-11-02 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
AU2008265974B2 (en) * 2007-06-13 2013-08-29 Ares Trading S.A. Use of TACI-Ig fusion protein such as atacicept for the manufacture of a medicament for treating Lupus Erythematosus
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
CA2786337A1 (en) 2010-02-04 2011-08-11 F. Hoffmann-La Roche Ag A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma
CN102337298B (en) * 2011-08-19 2013-11-06 黄开红 Immune nano-carrier for conveying siRNA (small interfering Ribonucleic Acid) and preparation method and application thereof
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
WO2017215637A1 (en) * 2016-06-15 2017-12-21 李翀 Human endometrial cancer marker, antibody, and application of antibody
CN107556388A (en) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 The double targeting antibodies of anti-CD44v6 and CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application
EP4301782A1 (en) * 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
WO1994012631A1 (en) * 1992-11-20 1994-06-09 Isis Innovation Limited Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
UA58482C2 (en) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх MONOCLONAL ANTIBODY VFF-18 AGAINST CD44v6 AND ITS FRAGMENTS
UY24389A1 (en) * 1995-12-06 2001-10-25 Karlsruhe Forschzent PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FLAT EPITHELIUM CARCINOMA

Also Published As

Publication number Publication date
JP2005504517A (en) 2005-02-17
WO2002094879A1 (en) 2002-11-28
SK15592003A3 (en) 2004-06-08
CZ20033476A3 (en) 2004-05-12
PE20021098A1 (en) 2003-02-11
ZA200307365B (en) 2004-05-10
BR0210905A (en) 2004-06-08
CA2443437A1 (en) 2002-11-28
HUP0400030A3 (en) 2006-02-28
EE200300569A (en) 2004-04-15
CN1541226A (en) 2004-10-27
EP1397387A1 (en) 2004-03-17
EA200301169A1 (en) 2004-06-24
HUP0400030A2 (en) 2004-04-28
PL365735A1 (en) 2005-01-10
YU91403A (en) 2006-05-25
AR036154A1 (en) 2004-08-18
ECSP034838A (en) 2003-12-24

Similar Documents

Publication Publication Date Title
MXPA03010523A (en) Antibodies specific for cd44v6.
SG170080A1 (en) Human monoclonal antibodies to o8e
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
SG10201408073XA (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
ATE516047T1 (en) OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ATE462726T1 (en) OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
MX2020012327A (en) Antagonizing cd73 antibody.
EA200800094A1 (en) ANTIBODIES CD19 AND THEIR USE
EA200970477A1 (en) HUMAN MONOCLONAL ANTIBODIES TO BTLA AND METHODS OF APPLICATION
MX2009003306A (en) Human antibodies that bind cxcr4 and uses thereof.
ATE420160T1 (en) MODIFIED RECOMBINANT VACCINIA VIRUSES, USES THEREOF
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2005097185A3 (en) Irta-5 antibodies and their uses
WO2007038637A3 (en) Human monoclonal antibodies to cd70
WO2006076691A3 (en) Irta-2 antibodies and their uses
HK1094876A1 (en) Method of producing recombinant antibodies against tumours
ATE514718T1 (en) PEPTABODY FOR CANCER TREATMENT
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
DE60230684D1 (en) SAK: MODULATION OF CELL PROLIFERATION FOR CANCER TREATMENT
UY27298A1 (en) CD44V6 SPECIFIC ANTIBODIES
PT914417E (en) DNASE II HUMANA
ATE463566T1 (en) TUMOR AND SENSENCE MARKERS
BR0210835A (en) Agrecanase Molecules